3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor in Research

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a high-affinity inhibitor of poly (ADP-ribose) polymerase (PARP), achieving over 95% inhibition at >1 μM concentration in CHO cells with minimal cytotoxicity (Grunewald et al., 2019). The compound improves endothelium-dependent nitric oxide-mediated vasorelaxation after oxidative stress. In diabetic db/db mouse models, it reduces albuminuria, mesangial expansion, and podocyte depletion. 3-Aminobenzamide is highly soluble in water, ethanol, and DMSO with ultrasonic assistance, and stable at −20°C for short-term storage. Its use extends research on DNA damage, cellular stress, and virus-host interactions, as supported by recent peer-reviewed studies and curated product data (product page).

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the transfer of ADP-ribose units from NAD+ to target proteins. This post-translational modification, known as ADP-ribosylation, regulates DNA repair, chromatin structure, cell death, and immune responses (Grunewald et al., 2019). Human cells encode 17 PARPs, with PARP1 being the most abundant and critical for DNA damage response. Inhibition of PARP activity is a validated strategy for studying genome maintenance, oxidative stress, and the pathogenesis of diseases such as diabetic nephropathy and viral infections. 3-Aminobenzamide (PARP-IN-1) is a well-characterized small molecule inhibitor that allows for the selective, reversible inhibition of PARP activity in vitro and in vivo (see product details).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide acts as a competitive inhibitor of PARPs by mimicking the nicotinamide moiety of NAD+, the natural substrate of PARP enzymes. By binding to the catalytic domain, it blocks the transfer of ADP-ribose polymers to target proteins. This inhibition prevents PARylation-dependent processes such as DNA strand break repair and chromatin remodeling (Grunewald et al., 2019). In cell-based assays, 3-Aminobenzamide achieves an IC50 of ~50 nM in CHO cells, indicating high potency. At concentrations above 1 μM, it provides over 95% inhibition of PARP activity without significant cytotoxicity, enabling its use in a broad range of cellular and animal models (see mechanism details).

Evidence & Benchmarks

• 3-Aminobenzamide (PARP-IN-1) inhibits PARP activity in CHO cells with an IC50 of approximately 50 nM under standard culture conditions (37°C, 5% CO₂) (Grunewald et al., 2019).
• At concentrations >1 μM, PARP inhibition exceeds 95% with no significant cytotoxicity in mammalian cells (product page).
• Improves acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation in models subjected to hydrogen peroxide-induced oxidative stress (internal article).
• Reduces diabetes-induced albumin excretion, mesangial expansion, and podocyte loss in db/db mouse models of diabetic nephropathy (internal article).
• Pan-PARP inhibition enhances coronavirus replication and suppresses interferon production in primary macrophages with macrodomain-mutant coronaviruses (Grunewald et al., 2019).

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely applied in:

• PARP activity inhibition assays in mammalian cell lines and tissue extracts.
• Modeling oxidant-induced myocyte dysfunction and endothelial responses to stress.
• Studying diabetic nephropathy mechanisms, particularly podocyte loss and proteinuria reversal.
• Investigating virus-host interactions, especially in the context of ADP-ribosylation and innate immunity (Grunewald et al., 2019).

This article extends the scope of previous summaries by providing updated evidence for low toxicity and improved workflow integration, and clarifies optimal storage/solubility parameters over mechanism-only reports. For further scientific depth, it differentiates itself from application-focused reviews by presenting new data on antiviral use cases.

Common Pitfalls or Misconceptions

• Not a pan-selective ADP-ribosyltransferase inhibitor: 3-Aminobenzamide is primarily effective against PARP1/2 and does not broadly inhibit all ADP-ribosylating enzymes.
• Not suitable for long-term solution storage: Stability drops significantly if dissolved solutions are stored beyond several days, even at −20°C.
• Not intended for diagnostic or therapeutic use: The compound is strictly for research purposes and is not approved for clinical application.
• Over-interpretation of in vitro potency: High efficacy in cell lines may not translate directly to complex in vivo systems due to pharmacokinetic constraints.
• Limited antiviral application: While PARP inhibition can affect viral replication, indiscriminate inhibition may suppress beneficial interferon responses (Grunewald et al., 2019).

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1) is provided as a solid with a molecular weight of 136.15 and chemical formula C₇H₈N₂O (CAS 3544-24-9). For optimal solubility:

• Water: ≥23.45 mg/mL with ultrasonic assistance.
• Ethanol: ≥48.1 mg/mL with ultrasonic assistance.
• DMSO: ≥7.35 mg/mL.

Store at −20°C. Avoid repeated freeze-thaw cycles. Prepare fresh solutions for each experiment. Shipments are made with Blue Ice to preserve integrity. Use at concentrations of 50 nM to 10 μM for most cell-based assays, with activity monitoring via PARP activity inhibition assays. For in vivo studies, dosing must be validated for each model system (A4161 kit).

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) remains a gold standard for PARP inhibition in research settings due to its high potency, specificity, and favorable solubility profile. Its validated use in models of oxidative stress, diabetic nephropathy, and virus-host interactions continues to support advances in molecular biology and translational science. Ongoing studies on ADP-ribosylation pathways may further expand its applications, but careful attention to dosing, specificity, and context is essential for reproducible results (Grunewald et al., 2019).